Project Grant R01CA259359
Award Date
2/1/22
Completion Date
1/31/27
Dollars Obligated
$360K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Cancer Institute awarded a $342,102 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Johns Hopkins University to elucidate the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The research aims to define how HMGA1 drives leukemogenesis and chemoresistance in this aggressive form of AML, and determine how HMGA1 induces the expression of key leukemogenic HOX genes and represses the CDKN1A tumor suppressor. This 2.25-year project,...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports scientific research to investigate the fundamental biological mechanisms underlying the development and progression of acute myeloid leukemia (AML). The $487,973 award, granted to The Leland Stanford Junior University, will fund a 5-year research project focused on understanding the role of pre-leukemic hematopoietic stem cells and clonal hematopoiesis in AML...
This $590,960 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program supports research at the Beckman Research Institute of the City of Hope to model the dynamics of the transcriptome and leukemia potential in acute myeloid leukemia (AML). The key objectives are to: 1) quantify leukemia potential dynamics driven by different oncogenic signals in murine models, 2) evaluate the effects of treatment on the leukemia potential to...
This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...
The National Cancer Institute (NCI) awarded a $768,437 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to implement high-throughput screening assays to identify chemical compounds that inhibit the chromatin reader SGF29. This project aims to develop novel chemical probes and potential therapeutic candidates for acute myeloid leukemia (AML), as SGF29 has been identified as a potent regulator of AML oncogene...
The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $415,259 Project Grant to the Rector & Visitors of the University of Virginia (UVA) to study the role and mechanism of noncoding RNAs in primary and relapsed acute myeloid leukemia (AML). The award, effective from August 1, 2024 to July 31, 2026, aims to understand how noncoding RNAs, specifically a PU.1 enhancer RNA, can modulate the RUNX1-ETO/PU.1 axis and serve as important regulators...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396), with a total obligated amount of $2,775,137, supports scientific research aimed at understanding the fundamental biological mechanisms underlying the progression of acute myeloid leukemia (AML) from pre-AML states such as age-related clonal hematopoiesis (ARCH), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). The research, conducted by The Trustees of Columbia...
This $487,542 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to understand the role of mitochondrial RNA modifications in acute myeloid leukemia (AML), a highly aggressive blood cancer. The research, conducted by the Beckman Research Institute of the City of Hope, aims to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, elucidate the molecular mechanisms by which...
This Project Grant award of $458,698 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to study novel genes that influence therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to identify cellular and molecular mechanisms underlying the persistence and regrowth of leukemic cells after treatment, with the goal of improving AML therapy and patient outcomes. Over the 5-year project period from...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) federal grant program provides funding to Harvard Medical School to conduct research aimed at understanding the mechanisms by which the MECOM gene regulates cell state and drives leukemogenesis in acute myeloid leukemia (AML). The $165,247 award, which began on July 26, 2024 and is scheduled to be completed by February 28, 2027, supports two key research objectives: 1) identifying the direct...